Effects of switching to extrafine medium strength triple therapy versus escalation of high strength dual-therapy regimen in patients with asthma or asthma-COPD overlap previously treated with medium-strength dual therapy (ERS 2026) - May 30, 2026 - Abstract #PA2580; Pres time: Sep 7, 2026; 08:00 AM - 09:30 AM; Location: PS-14; Board Number: 19; "For patients whose asthma remains uncontrolled on medium strength (MS) ICS/LABA, GINA guidelines recommend stepping up to high strength (HS) ICS/LABA or using MS ICS/LABA/LAMA such as beclometasone/formoterol/glycopyrronium (BDP/FF/G)...1). Patients received significantly less ICS inhalers and lower mean daily ICS exposure with no significant difference of mean daily OCS exposure.Extrafine MS BDP/FF/G is an effective alternative to HS ICS/LABA for with asthma or asthma-COPD overlap patients escalating from MS ICS/LABA, delivering comparable control with lower CS dose."
Clinical • Asthma • Chronic Obstructive Pulmonary Disease • Immunology • Respiratory Diseases
|
|
D. Price; G. Brusselle; C. Grainge; L. Di Palma; A. Piraino; V. Carter; U. Scaffidi-Argentina; L. Franzini; A. Gayle; W. Henley; D. Skinner; A. Streeter; D. Singh; N. Roche
|